FDA Publishes a PCCP Page With a List of 240 Devices; 20 Records Not on the List Have PCCP Review Language in Their Letters
On October 20, 2026, FDA's Center for Devices and Radiological Health (CDRH) published a page titled "Predetermined Change Control Plans." Along with general information on PCCPs, it carries a list of devices FDA has authorized with a PCCP: 240 entries with decision dates from July 21, 2023 to September 30, 2026, each with the decision date, submission number, device, company, lead review panel and primary product code. The page does not say what period the list is meant to cover.
The same day, FDA published hypothetical case examples showing how PCCPs might be used for novel AI-enabled devices. One of the two is arrhythmia detection software that retrains itself once enough new annotated data accrues and goes from retraining to deployment at every site with no human decision-making.
Checked against RA Craft Database records, 20 510(k)s show sources that do not agree. They are not on the list and read No in the PCCP field on FDA's record pages, yet FDA's clearance letters say the determination "also included the review and clearance" of a PCCP. Below, records whose plan can be confirmed in other text are kept apart from those with only the letter's standard paragraph.
What the page says
The page describes a PCCP as a description of planned modifications to a device, how the manufacturer will develop, test and implement them, and how it will assess their impact, authorized by FDA as part of a marketing submission. Changes made within an authorized PCCP and implemented as it specifies do not need a new marketing submission each time.
A PCCP can include planned modifications that:
- would otherwise require a new marketing submission,
- keep the device within its intended use, and
- for 510(k) devices, allow it to remain substantially equivalent to the predicate.
It has three parts: a Description of Modifications, a Modification Protocol and an Impact Assessment. The protocol covers performance evaluation with predefined acceptance criteria for each modification, the update procedure and, where applicable, how users will be notified. The impact assessment covers the individual and cumulative effect of each modification, how one modification affects another, their benefits and risks, and how the protocol keeps the device safe and effective. FDA says the level of detail should be similar to the rest of the submission.
PCCPs can be included in 510(k), De Novo and PMA submissions, including device-led combination products. A PCCP goes in its own section and is discussed in the cover letter; in eSTAR it is flagged in the General Device Characteristics section of the Device Description with a checkbox and an attachment. Questions go to rpg@fda.hhs.gov. Listed resources include the September 2023 final guidance on updating antimicrobial susceptibility test (AST) breakpoints, the August 2024 draft guidance on PCCPs for medical devices in general, and the August 2025 final guidance on PCCPs for AI-enabled device software functions.
The 240: more than half are 510(k)s from 2025 on
Counts here are by submission number. Separate submissions for the same product, and several PMA supplements covering the same plan, are counted separately, so the counts are not numbers of distinct products or unique change control plans.
| Decision year | 510(k) | De Novo | Original PMA | PMA supplement | Total |
|---|---|---|---|---|---|
| 2023 | 4 | 0 | 0 | 0 | 4 |
| 2024 | 22 | 2 | 0 | 5 | 29 |
| 2025 | 72 | 1 | 2 | 29 | 104 |
| Jan–Sep 2026 | 76 | 3 | 2 | 22 | 103 |
| Total | 174 | 6 | 4 | 56 | 240 |
The earliest entry is Apple's Irregular Rhythm Notification Feature (K231173), decided July 21, 2023. The list is concentrated in 2025 (104) and the first nine months of 2026 (103). Month by month, the list's 2026 entries ran 6, 10, 9, 10, 10, 10, 18, 15 and 15.
Cardiovascular is the largest lead panel with 67 entries, followed by radiology (52), microbiology (47), clinical chemistry (17), and pathology and neurology (13 each). By product code, QIH, for radiological image processing software, leads with 25, followed by JWY (14) and JTN (13). Forty-one rows name a Medtronic company: counting spelling variants together, 26 Medtronic, Inc., 7 each for Medtronic Cardiac Rhythm Disease Management and Medtronic MiniMed, and 1 Medtronic Sofamor Danek.
RA Craft Database has confirmed AI/ML in its public documents for 75 of the 240: 72 510(k)s, 2 De Novos and 1 original PMA, and none of the PMA supplements. The other 165 are not thereby shown to be non-AI.
The 56 PMA supplements: mostly manufacturing and supplier changes
Each PMA supplement's database record has an Approval Order Statement that says in a sentence what was approved. Forty-six of the 56 statements mention a PCCP, and 36 of those (about four in five) plan changes to manufacturing processes, component or tissue suppliers, or plant facilities.
- Biocompatibility-related manufacturing changes (24): On March 20, 2025, the same PCCP was approved across 24 Medtronic PMAs for pacemakers, implantable defibrillators, leads and related devices (for example, P150033S201). It covers removing a processing aid or cleaning agent, removing a cleaning process, and changing cleaning parameters such as temperature, time or sonication, "provided that they do not impact the properties of the device materials."
- New tissue suppliers (7): On February 12, 2026, seven Medtronic PMAs, including bioprosthetic heart valves, received a PCCP (for example, P980043S086) setting a standardized process to qualify new bovine and porcine tissue suppliers, provided tissue specifications and sourcing, handling and testing methods do not change.
- Facilities and sites: installing a semi-automated packaging line and expanding cleanrooms at Abbott's pacing lead plant (June 11, 2026, two supplements), a new manufacturing location for a TactiFlex ablation catheter subassembly (September 22, 2026), a new compressor membrane model for the IKUS driving unit (July 24, 2025), and second-source catheter components (March 23, 2026).
- Software and electronics: running Abbott's neurostimulator patient controller app on iOS (June 26, 2024, three supplements), hardware and software changes to the TRUPULSE generator (June 30, 2026, two), an alternate microcontroller for the Tula System (February 1, 2024), noninvasive blood pressure modules and cleaning changes for the LIFEPAK 35 (April 12, 2024), alternate primary user interfaces and display compatibility (January 23, 2026), and minor assay software and instrument changes (February 6, 2025).
- More testing sites: a plan to let a test performed at a single laboratory be performed at multiple laboratories (September 2, 2026). This is the only statement that calls it a "Pre-specified Change Control Plan."
Ten supplement statements do not mention a PCCP. Seven, dated August 7, 2026 and filed under Abbott-related names (Abbott Medical, St. Jude Medical, Irvine Biomedical), approve firmware changes so ablation equipment stays compatible with a new catheter; the others cover alternate printed circuit board components (two) and catheter packaging (one). Their statements do not say what the PCCP covers, but each record's "Predetermined Change Control Plan Authorized" field reads Yes.
By supplement type, 35 are "135 Review Track For 30-Day Notice," 11 "Normal 180 Day Track" and 10 "Real-Time Process."
Checking the list against RA Craft Database: 23 records not on the list
All 240 entries are records RA Craft Database holds, and RA Craft Database shows all of them as PCCP-authorized. It counts a record as PCCP-authorized when either FDA's record (the PCCP field on the record page, or this list) or a public document it has checked confirms a PCCP. Under that rule it counts 263 PCCP-authorized records through September 30, 2026, 23 more than FDA's list. The 263 include the four records whose only basis is the letter's standard paragraph (below), and they are RA Craft Database's count, not a total FDA has published. For January to September 2026 the count is 113 (7, 12, 9, 10, 10, 13, 18, 16 and 18 by month).
Twenty 510(k)s not on the list, with No in the PCCP field and PCCP language in the letter
Twenty of the 23 are 510(k)s whose clearance letters say "FDA's substantial equivalence determination also included the review and clearance of your Predetermined Change Control Plan (PCCP)." They were decided between October 2024 and September 2026, within the range of decision dates on the list. Yet none of the 20 is on the list, and on every record page the "Predetermined Change Control Plan Authorized" field reads No. FDA has not said which source is right or why these records are not on the list.
| Decision | Number | Device | Company | Beyond the letter |
|---|---|---|---|---|
| Oct 2, 2024 | K241561 | MammoScreen BD | Therapixel | Plan described in the Summary |
| Oct 17, 2024 | K240408 | REMI-AI Rapid Detection Module | Epitel | Plan described in the Summary |
| Nov 8, 2024 | K240417 | ProFound Detection (V4.0) | iCAD | Plan described in the Summary |
| Nov 22, 2024 | K242094 | Dreem 3S | Beacon Biosignals | Plan described in the Summary |
| Jan 3, 2025 | K241350 | Clarify DL | GE Medical Systems Israel | Plan described in the Summary |
| Jan 10, 2025 | K241891 | ScreenDx | Imvaria | Plan described in the Summary |
| Jan 15, 2025 | K243065 | Cardiac Guidance | Caption Health | Plan described in the Summary |
| Feb 12, 2025 | K243250 | SubtleHD (1.x) | Subtle Medical | Plan described in the Summary |
| Apr 2, 2025 | K250705 | Sonata Transcervical Fibroid Ablation System 2.2 | Gynesonics | Letter's standard paragraph only |
| Dec 5, 2025 | K251657 | Personalized Therapy Comfort Settings | ResMed | Plan described in the Summary |
| Jan 9, 2026 | K252589 | Corvair Monza | AliveCor | Plan title in the letter; described in the Summary |
| Feb 13, 2026 | K251928 | CoolCryo | Medinice | Letter's standard paragraph only |
| Feb 24, 2026 | K260217 | AI Platform 2.2 | Exo Imaging | Keeps the predicate's PCCP; Summary says this submission's modifications are outside its scope |
| Jun 2, 2026 | K252844 | Tyto Insights for Wheeze Detection (with PCCP) | Tyto Care | Plan described in the Summary |
| Jun 4, 2026 | K252575 | Tuff Cuff Disposable Surgical Gowns | New York Embroidery Studio | Plan title in the letter (no public Summary) |
| Jun 11, 2026 | K260322 | Acorn 3D Software | Mighty Oak Medical | Plan described in the Summary (plan cleared in K234009) |
| Aug 5, 2026 | K261380 | Concentriq AP-Dx | Proscia | Plan described in the Summary |
| Sep 11, 2026 | K254123 | Ecomed Disposable Administration Sets | Ecomed Solutions | Letter's standard paragraph only |
| Sep 11, 2026 | K260001 | Mint ACE Pump | Beta Bionics | Plan described in the Summary |
| Sep 18, 2026 | K254095 | 25G Huber Needle | Martech Medical Products | Letter's standard paragraph only |
For 16 of the 20, text beyond the letter's sentence confirms the plan. For 14, the 510(k) Summary describes what the plan covers. Most are AI retraining or algorithm improvements (for example AliveCor's Corvair Monza and Tyto Care's wheeze detection software); others add imaging systems or scanners (iCAD's ProFound Detection, Proscia's Concentriq AP-Dx) or compatible insulins (Beta Bionics' Mint ACE Pump). Tyto Care's record even has "(with PCCP)" in the device name. The surgical gown (K252575) has no public Summary, but its letter names the plan, "VAL-S002 Predetermined Change Control Plan (PCCP), version rev0.3." Exo Imaging's AI Platform 2.2 (K260217) says it continues to contain the PCCP of its predicate (K240953), and that the modifications in this submission are outside that PCCP's scope. A record that keeps a PCCP does not mean the changes reviewed in that submission fall within the plan. RA Craft Database has confirmed AI/ML for 13 of the 20.
The other four mention a PCCP only in the letter's standard paragraph, with no plan title and nothing in the Summary: Gynesonics' fibroid ablation system (K250705), Medinice's cardiac cryoablation device (K251928), Martech Medical Products' 25G Huber Needle (K254095) and Ecomed Solutions' administration sets (K254123). FDA has corrected letters before because this paragraph was included in error (the four cases below). But that history, or a No in the record field, does not make these four errors as well. Whether they actually have a PCCP or the letter template was misapplied cannot be told from the public documents. When RA Craft Database opened their PDFs on October 21, 2026, none contained a correction letter.
Three records with PCCP language from before the list's earliest decision
The earliest decision date in the retrieved list is July 21, 2023. Public documents for three earlier records also describe PCCPs; they are the remaining three of the 23. Caption Health's Caption Guidance (K201992, September 2020) and Medtronic's LINQ II insertable cardiac monitor with Zelda AI (K210484, June 2021) describe a PCCP in their 510(k) Summaries. Caption Health's Caption Interpretation (DEN220063, February 2023) is a De Novo whose classification order says FDA's decision included review of the PCCP, and the new device type it created has "predetermined change control plan" in its name. All three read No in the record page's PCCP field. FDA has not said why they are not on the list.
Six records not counted: four correction letters and two references to existing plans
RA Craft Database counts a record when FDA's decision document for that submission (the 510(k) clearance letter or the De Novo classification order) says a PCCP was reviewed and authorized; K201992 (2020) and K210484 (2021), whose letters do not carry that sentence, are counted because their Summaries say a PCCP was submitted in that application. On that line, six records with PCCP language are not counted, for two different kinds of reason.
For four (K231837, K233109, K233692, K233734), FDA later issued correction letters saying the original letter's statement that the submission included a PCCP was in error and the 510(k) did not include one (for K231837, a correction dated June 28, 2024). FDA corrected an erroneous statement; this was not a withdrawal of the device's clearance.
The other two have no PCCP review language in the letter, and their Summaries refer to an existing PCCP. Mighty Oak Medical's Acorn 3D Software (K252103, December 2025) says future algorithm improvements will be made under the PCCP cleared in K234009, with no changes to that PCCP in this submission. That shows the existing plan continues to apply to the product, but not that the PCCP was reviewed again in this submission. The same product's June 2026 submission, K260322, is counted because its letter does carry the PCCP review language. GE's Venue Go (K261668, August 2026) only notes that the integrated Caption Guidance has its own clearance with an approved PCCP (K243065). Leaving these two out does not mean they have no PCCP; it means their decision documents do not show a PCCP review in that submission.
When you research a predicate's PCCP, FDA's list and the record page's PCCP field are not enough; open the clearance letter, the 510(k) Summary and the Decision Summary too. In the other direction, some letters carry only the standard paragraph with nothing to show what the plan covers, and in some cases FDA corrected a letter's erroneous statement that the submission included a PCCP.
The hypothetical cases: an AI that goes from retraining to deployment without human decision-making
FDA's "Novel Medical Devices with Predetermined Change Control Plans: Hypothetical Case Examples" walks through the three parts of a PCCP for two fictional AI devices. FDA says the examples are illustrative and not complete PCCPs, though "they may be representative of the level of information provided in a public device summary about a PCCP."
The first is software that scores sepsis risk from hospital electronic health record data and raises alerts. A "global" model trained on a multi-site national dataset is adapted to each hospital through three modifications: reweighting structured nursing documentation inputs within a preset range, retraining the model's final output layers on local data, and moving the alert threshold within a preset range. Input reweighting is limited to structured, coded nursing documentation; free-text fields are excluded. The architecture, feature set, risk score calculation and input and output data types stay fixed. Local adaptation is manual, each site's deployment needs the manufacturer's review and approval, and a site can revert to the global model. Because the first modification affects the other two and the second affects the third, the order of implementation is fixed as well.
The second is titled "Continuously Learning Cardiac Arrhythmia Detection Software," for inpatient ECG telemetry. Retraining starts automatically when a preset number of newly annotated rhythm strips accrue; per-class thresholds are then re-evaluated, and the updated model is validated automatically, per arrhythmia class and per subgroup, against an independent test set sequestered before training. If every criterion passes, it rolls out to all sites in stages; if any fails, deployment is blocked and the manufacturer alerted. FDA writes that the changes are implemented "without human input, action, review or decision-making," names the absence of a human in the loop when modifications are implemented, validated and deployed as a risk, and points to the deployment block and automated post-deployment monitoring, with drift thresholds that trigger manufacturer review, as the controls. The user interface shows the model version and last update date, and the instructions for use are updated.
Part two of our monthly PCCP series covered a September 2026 plan that retrains daily on each unit and activates the result after evaluation. In FDA's hypothetical, retraining, validation and the decision to deploy to every site are all automated.
Finding them in RA Craft Database
On Search, the PCCP filter lists PCCP-authorized records, including the 23 that are not on FDA's list. Star (☆) devices and line them up in the comparison table in My Workspace to compare indications and document links. Each month's PCCPs are covered in our monthly PCCP series (part one for September 2026).
FDA's list was taken from the table on its "Predetermined Change Control Plans" page (published October 20, 2026) on October 21, 2026. Approval Order Statements and supplement types for PMA supplements were checked on each record in FDA's PMA database (updated October 19, 2026). The comparison with RA Craft Database and the AI/ML counts use RA Craft Database data loaded on October 7, 2026 (records with FDA decision dates through September 30, 2026), tallied by submission number on October 21, 2026. RA Craft Database counts a record as PCCP-authorized when either FDA's record (the PCCP field on the record page, or FDA's list) or its own check of public documents on October 21, 2026 confirms it; records FDA has said in a correction letter did not include a PCCP, and records whose decision document has no PCCP review language and that only refer to an existing PCCP, are excluded. Counts are by submission number. The saved copy of FDA's list (CSV) also holds RA Craft Database's PCCP display from before the rule was changed. Letter wording was checked in the PDFs FDA publishes on October 21, 2026. AI/ML status is what RA Craft Database could confirm in public documents. RA Craft Database's counts are not official FDA statistics.
RA Craft Database is an independent service and is not affiliated with or endorsed by the U.S. FDA. Articles are for general information on product development and regulatory research; they are not legal or regulatory advice for a specific device. Official FDA documents remain the authoritative source.
← All articles